TUSTIN, Calif., Dec. 19 /PRNewswire-FirstCall/ -- AMDL, Inc., (Amex: ADL), today announced that its subsidiary, Jade Pharmaceutical Inc., a developer, manufacturer, and marketer of pharmaceutical, nutraceutical, diagnostic, consumer healthcare and personal care products, is set to open its first large-scale JPGreen Health and Personal Care Center in Hangzhou, China. The state-of-the-art facility was acquired by Jade to be converted into a flagship JPGreen Health and Personal Care Center.
Customers will experience full service personal health care, which will include the anti-aging treatment with Jade's award winning Goodnak(R) product. The Hangzhou Center is the first full service location of an anticipated 200 JPGreen Health and Personal Care Centers. "Individual locations are expected to have an average gross profit margin of 70% and these Care Centers will add significantly to our sales. We previously announced that Goodnak(R) distributor sales alone are on a path to deliver revenues as high as $24 million over the next 12 months," said Frank Zhen, managing director.
Gary Dreher, CEO of AMDL, said that the "previous distributor network of sales and the new non distributor revenue provided by Jade's own growing consumer health and personal care business complement the Company's other already profitable product lines. We are building on the significant success we achieved in China this past quarter."
About AMDL: More information about AMDL and its products can be obtained at http://www.amdl.com.
About Jade: Jade has access to the fastest growing pharmaceutical and consumer market in the world: China. AMDL, through its Jade subsidiaries, currently holds licenses for 133 products that are manufactured as large volume injection fluids, tablets and other related products. It currently manufactures over 20 key generic, over the counter and supplemental pharmaceutical products under certified Chinese Good Manufacturing Practice (CGMP) standards.
This news release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Such
statements are subject to certain risks and uncertainties, and actual
circumstances, events or results may differ materially from those projected
in such forward-looking statements. The Company cautions readers not to
place undue reliance on any forward-looking statements. The Company does
not undertake, and specifically disclaims any obligation, to update or
revise such statements to reflect new circumstances or unanticipated events
as they occur.
Contact: AMDL, Inc.
Mr. Paul Knopick
AMDL Investor Relations
Direct Line: 949.707.5365
|SOURCE AMDL, Inc.|
Copyright©2007 PR Newswire.
All rights reserved